- Cannabix Technologies (BLO) has been granted a U.S. patent for its FAIMS molecular analysis device
- The patent covers innovations with Cannabix’s FAIMS (field asymmetric waveform ion mobility spectrometry) cannabis breathalyzer technology
- The company is developing a FAIMS-based drug screening device to help labs and law enforcement detect cannabis in exhaled breath
- Cannabix Technologies is a developer of cannabis breathalyzer technologies
- Cannabix Technologies (BLO) is up by 10.99 per cent and is currently trading at $1.01 per share
Cannabix Technologies (BLO) has been granted a U.S. patent for its FAIMS molecular analysis device.
The patent, entitled “Apparatus and Methods for Detection of Molecules”, is centered on innovations with the company’s FAIMS (field asymmetric waveform ion mobility spectrometry) cannabis breathalyzer technology.
Areas of innovation include ion mobility spectrometry, non-volatile molecule sampling and fluid dynamics, all of which provide utility related to the detection of target molecules in the breath.
The company is developing a FAIMS-based drug screening device to help laboratories and law enforcement detect cannabis in exhaled breath. The device uses ion mobility filtering techniques related to mass spectrometry and can be coupled directly to a mass spectrometer for validation with gold standard techniques.
The device was previously granted two patents by the Canadian Intellectual Property Office and the United States Patent and Trademark Office, both entitled “Cannabis Drug Detection Device”.
Cannabix Technologies is a developer of cannabis breathalyzer technologies.
Cannabix Technologies (BLO) is up by 10.99 per cent and is currently trading at $1.01 per share as of 10:04 am ET.